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Azosemide is more potent than 
bumetanide and various other loop 
diuretics to inhibit the sodium-
potassium-chloride-cotransporter 
human variants hNKCC1A and 
hNKCC1B
Philip Hampel  1,2, Kerstin Römermann1, Nanna MacAulay  3 & Wolfgang Löscher1,2
The Na+–K+–2Cl− cotransporter NKCC1 plays a role in neuronal Cl− homeostasis secretion and 
represents a target for brain pathologies with altered NKCC1 function. Two main variants of NKCC1 
have been identified: a full-length NKCC1 transcript (NKCC1A) and a shorter splice variant (NKCC1B) 
that is particularly enriched in the brain. The loop diuretic bumetanide is often used to inhibit NKCC1 
in brain disorders, but only poorly crosses the blood-brain barrier. We determined the sensitivity of the 
two human NKCC1 splice variants to bumetanide and various other chemically diverse loop diuretics, 
using the Xenopus oocyte heterologous expression system. Azosemide was the most potent NKCC1 
inhibitor (IC50s 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B), being about 4-times more potent 
than bumetanide. Structurally, a carboxylic group as in bumetanide was not a prerequisite for potent 
NKCC1 inhibition, whereas loop diuretics without a sulfonamide group were less potent. None of the 
drugs tested were selective for hNKCC1B vs. hNKCC1A, indicating that loop diuretics are not a useful 
starting point to design NKCC1B-specific compounds. Azosemide was found to exert an unexpectedly 
potent inhibitory effect and as a non-acidic compound, it is more likely to cross the blood-brain barrier 
than bumetanide.
The Na+–K+–2Cl− cotransporter NKCC1 (encoded by SLC12A2) plays an important role in Cl- uptake in neu-
rons both in developing brain and in adult sensory neurons1,2. Alterations in the expression and function of 
NKCC1 have been implicated in several brain disorders, including neonatal seizures, epilepsy, autism, cerebral 
edema following ischemic and traumatic brain injury, and in chronic and acute pain1,3–5. Indeed, experimen-
tal studies indicate beneficial modulation of NKCC1 in models of these pathologies. Currently, bumetanide, a 
5-sulfamoylbenzoic acid derivative loop diuretic, is the only drug that is used to inhibit neuronal NKCC1 in neu-
rological or psychiatric disorders5. The potent diuretic effect of bumetanide is mediated by inhibition of NKCC2 
(SLC12A1) in the thick ascending limb of the loop of Henle (TALH)6. Bumetanide reaches its target (NKCC2) in 
the kidney by active renal uptake mediated by organic anion transporters (OATs [SLC22A])7,8. However, in most 
other tissues, including the brain, only very low bumetanide concentrations are reached9–11. The low brain con-
centrations of bumetanide obtained after systemic administration are thought to result from its high ionization 
(>99%) at physiological pH and its high plasma protein binding (>95%), which restrict brain entry by passive 
diffusion, as well as active efflux transport at the blood-brain barrier(BBB)9,10. The poor brain penetration of 
bumetanide is a likely explanation for its controversial efficacy in the treatment of brain diseases11–13.
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We have recently reported that BBB permeant prodrugs of bumetanide may provide a strategy to overcome the 
poor brain penetration of this drug14,15. However, this strategy would not resolve potential problems associated 
with NKCC1 inhibition in other tissues, including its ototoxicity in the inner ear13,16,17. In cells and tissues from 
different mammalian species, including rodents and humans, two major, alternatively spliced RNA variants of 
NKCC1 have been identified: a full-length NKCC1 transcript (NKCC1A) and a shorter splice variant (NKCC1B); 
both of which form functional cotransporters when expressed in heterologous systems18, and vary in their distri-
bution in humans and other mammals2,18–20. Both NKCC1A and NKCC1B transcripts are expressed in the human 
brain, but the ratio of hNKCC1B to hNKCC1A expression is significantly higher in the brain, when compared 
with other tissues18. The functional significance and pharmacological sensitivity of the two main NKCC1 splice to 
various inhibitors is unknown. Developing pharmacological tools selectively targeting each variant has a potential 
impact on elucidating the function of these variants, as well as possible therapeutic implications for the treatment 
of various neurological and psychiatric disorders. In addition to hNKCC1A and hNKCC1B, two other splices 
variants of hNKCC1 have been reported recently20, but their tissue distribution and function are not yet known.
In the present study, we determined the sensitivity to bumetanide and other loop diuretics of the two main 
hNKCC1 splice variants, using the Xenopus oocyte heterologous expression system and radiolabeled rubidium 
(86Rb+) to measure NKCC-mediated ion flux. Our study had two major aims. First, we wanted to characterize the 
pharmacological profile of the hNKCC1A and hNKCC1B by using loop diuretics from different structural groups 
(see Results), thus allowing structure-activity analyses. Second, because to the best of our knowledge, except for 
bumetanide and furosemide, none of the chemically diverse loop diuretics used here have previously been tested 
for inhibitory effects on hNKCC1, we wanted to evaluate whether any of these drugs inhibit hNKCC1 with similar 
or higher potency than bumetanide, but, based on structure, physicochemical properties, and pharmacokinetics 
may have advantages vs. bumetanide for treatment of brain diseases with abnormal cellular chloride homeostasis.
Materials and Methods
Drugs. All chemicals were purchased from Sigma Aldrich Chemie GmbH (Schnelldorf, Germany), unless 
otherwise stated. Torasemide came from Absource Diagnostics GmbH (Munich, Germany), azosemide from 
MolPort SIA (Riga, Latvia), and tripamide from Shanghai Laihao Trade Co., Ltd (Shanghai, China). All NKCC 
inhibitors were dissolved in dimethyl sulfoxide (DMSO; <1% DMSO in final solution). Lipophilicity (logP) and 
acidic dissociation constant (pKa) of some of the drugs were taken from the DrugBank database (https://www.
drugbank.ca/drugs/).
Oocyte preparation and NKCC1 protein expression. Oocytes from Xenopus laevis were obtained from 
our own frogs (Laboratory Animal Science, Centre for Medical Sciences, Hannover Medical School, Germany). The 
surgical removal and preparation of defolliculated oocytes was performed as previously described21. Experiments 
were performed according to the European Union Guidelines for Animal Welfare (Directive 210/63/EU) 
and the German Law on Animal Protection (“Tierschutzgesetz”). Ethical approval for the study was granted by 
an ethical committee (according to §15 of the Tierschutzgesetz) and the governmental agency (Lower Saxony 
State Office for Consumer Protection and Food Safety; LAVES) responsible for approval of animal experiments in 
Lower Saxony (reference number for this project 15/1825). All efforts were made to minimize both the suffering 
and the number of animals.
Human NKCC1A (NM_001046, obtained from Prof. Biff Forbush, Yale School of Medicine, CT) and 
NKCC1B (prepared by site-directed mutagenesis from hNKCC1A as described below) were subcloned into the 
oocytes expression vector pXOOM, linearized downstream from the poly-A segment, and in vitro transcribed 
using T7-mMessage Machine according to manufacturer’s instructions (Ambion, Austin, TX). cRNA was then 
extracted with MEGAclear (Ambion, Austin, TX) and micro-injected into defolliculated Xenopus laevis oocytes 
(25 ng RNA/oocyte). The oocytes were kept in Kulori medium (in mM: 90 NaCl, 1 KCl, 1 CaCl2, 1 MgCl2, 5 Hepes, 
pH 7.4, 182 mOsm) for 5–6 days at 19 °C prior to experiments.
The difference between hNKCC1A (NM_001046) and hNKCC1B (NM_001256461) is 48 base pairs18. To 
obtain the cDNA encoding NKCC1B, two rounds of PCR (each deleting 24 base pairs from the sequence) was 
carried out with the following primer sets: shNKCC1A-B, 1–24: aaaaaccaattacacac.actgcaactcaaccact; ahNKC-
C1A-B, 1–24: agtggttgagttgcagtgtgtgtaattggttttt and shNKCC1A-B, 25–48: aaaaaccaattacacac_aaagaatccaaaggccc; 
ahNKCC1A-B, 25–48: gggcctttggattcttt gtgtgtaattggttttt. The entire sequence of the final construct was verified 
against hNKCC1B (NM_001256461).
NKCC1A and NKCC1B activity assay. To activate NKCC1A and NKCC1B prior to the 86Rb+ uptake meas-
urements aimed at measuring NKCC-mediated fluxes, hNKCC1A- or hNKCC1B-expressing oocytes or unin-
jected control oocytes (4–13 oocytes per well) were pre-incubated for 30 min at room temperature in a K+-free 
solution (containing in mM: 5 choline chloride, 95 NaCl, 1 MgCl2, 1 CaCl2, 10 Hepes, pH 7.4, 207 mOsm), which 
causes shrinkage of the oocyte and thus activation of NKCC1A22. To measure K+ influx, oocytes were exposed 
to an isosmotic test solution in which KCl (5 mM) replaced choline chloride, and 2 μCi/mL 86Rb+ (NEZ072, 
PerkinElmer, Rodgau, Germany) were included as a tracer for K+. Osmolarities of the test media were veri-
fied by using an osmometer (Type 15, Löser; Berlin, Germany). Different concentrations of drugs or control 
vehicle (≤1%; ensuring equal exposure to relevant drug solvent of all tested oocytes in the given experiment) 
were added to the test solution. The uptake assay was performed at room temperature for 5 min, which has been 
demonstrated to be within the linear phase of K+ uptake22. The influx experiments were terminated by 3 rapid 
washes in ice-cold 86Rb+-free assay solution after which the oocytes were individually dissolved in 50 µl 10% 
sodium dodecyl sulfate in scintillation vials. The radioactivity was determined by liquid scintillation β-counting 
with Aquasafe 300 Plus scintillation cocktail (Zinsser Analytic GmbH, Frankfurt, Germany) using a Microbeta 
Trilux (Perkin Elmer). hNKCC1-mediated K+ uptake was assessed as ([fluxNKCC1-expressing oocytes in presence of 
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x µM drug]−[fluxuninjected oocytes in presence of x µM drug]), in order to correct for endogenous NKCC activity. All 
experiments were repeated at least three times (range 3–7) with 4–20 (in most experiments at least 10) oocytes 
per drug concentration per experiment.
Western blotting of hNKCC1A and hNKCC1B in injected oocytes. Five to six days after micro- 
injection of hNKCC1A or hNKCC1B cRNA, single oocytes and respective uninjected oocytes were homogenized 
on ice by trituration through 23G cannulas in 20 µl lysis buffer per oocyte (20 mM Tris-HCl, 140 mM NaCl, 2% 
(v/v) Triton X-100) supplemented with complete protease inhibitor (Roche, Mannheim, Germany). Samples were 
stored at −20 °C until Western Blot analysis.
Protein concentrations were determined by using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific, 
Darmstadt, Germany). 20 µg of total protein per sample were separated on 10% polyacrylamide gels under reduc-
ing conditions and transferred to PVDF membranes which were blocked for 2 h at room temperature (RT) in 
5% nonfat milk in phosphate buffered saline supplemented with Tween-20 (PBST: 137 mM NaCl, 2.7 mM KCl, 
4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.3, 0.05% (w/v) Tween-20). Membranes were cut at 70 kDa, incubated 
overnight with rabbit polyclonal anti-NKCC1 antibody (ab59791, Abcam, Cambridge, UK) 1:1000 and rabbit 
polyclonal anti-β-actin 1:5000 (Sigma-Aldrich, Taufkirchen, Germany) respectively, in 2% milk in PBST shaking 
at 4 °C and washed three times for 10 min in PBST. Ab59791 binds to the N terminal region of hNKCC1 and 
reacts with NKCC1 from human, mouse and rat. As the immunogen sequence is to 95% homologous to Xenopus 
laevis Nkcc1, it is likely to cross-react with the endogenous protein in frog oocytes (see Results). Secondary 
antibody goat anti-rabbit-HRP 1:1000 (Dako, Hamburg, Germany) was incubated for 1 h in 2% milk in PBST at 
RT and washed three times for 10 min in PBST. Proteins were detected by enhanced chemiluminescence using 
SuperSignal West Femto Chemiluminescent Substrate (Thermo Fisher Scientific) and the Chemidoc™ XRS 
Imager (Bio-Rad Laboratories, Munich, Germany). Relative protein expressions were quantified densitometri-
cally (after subtracting background staining) with Quantity One 1-D Analysis software (Bio-Rad Laboratories) 
and calculated by normalization to the reference signals of β-actin with Microsoft® Excel 2010 (Microsoft 
Corporation, Redmond, USA) and GraphPad Prism 7.0 software (GraphPad, San Diego, CA, USA).
Data analysis and statistical methods. Sigmoidal curves were fitted to the data for determination of 
the IC50 value for loop diuretics using GraphPad Prism 7.0, according to a dose-response inhibition curve with 
log (inhibitor vs. response, variable slope; Y = Min + (Max-Min)/(1 + 10^((LogIC50-X)*HillSlope)) and for 
experiments with fewer concentrations assuming the curves would reach complete inhibition (going from 100% 
to 0 according to a dose-response inhibition curve with log(inhibitor) vs. normalized response, variable slope; 
Y = 100/(1 + 10^(X-LogIC50)). IC50 values were obtained from each individual experiment, and averaged (using 
the median) across all experiments (at least 3) with the given drug to obtain an average IC50. Median rather than 
mean values were used because oocyte data on 86Rb+ uptake measurements were not normally distributed.
Although different batches of oocytes express minor differences in hNKCC1A or B levels, we did not observe 
any trends towards batch-specific differences in the IC50s of loop diuretics; therefore differences in expression lev-
els should not affect the obtained values (with the exception of ethacrynic acid; see Results). All experiments are 
shown with median and interquartile range (or 95% confidence limits), whereas IC50s are presented as medians 
and ranges, in which the range was calculated from the number of experiments (3–7) per compound. Significance 
of differences in transport activity of hNKCC1A or hNKCC1B expressing oocytes vs. uninjected oocytes were 
analyzed by the Kruskal-Wallis test followed by Dunn’s multiple comparisons test. The Mann-Whitney test was 
used to calculate whether drug effects on hNKCC1A and hNKCC1B differed significantly. A P < 0.05 was con-
sidered significant.
Data availability. The datasets generated and analyzed during the current study are available from the cor-
responding author on reasonable request.
Results
Structural diversity of loop diuretics used for studying the pharmacological sensitivity of 
hNKCC1A vs. hNKCC1B. As shown in Fig. 1, loop diuretics with different chemical structures can be clas-
sified into three groups; (1) 5-sulfamoylbenzoic acid derivatives furosemide, bumetanide, piretanide and benz-
metanide; (2) the azosemide group, i.e., non-acids with a sulfonamide moiety, such as azosemide (axosemide), 
torasemide (torsemide), tripamide, and tizolemide, and (3) non-sulfonamides of different structure, which 
include both carboxylic acids like ethacrynic acid, ticrynafen (tienilic acid), indacrinone, and ozolinone, and 
non-acids such as etozolin and muzolimine. All these chemically different loop diuretics act by inhibiting NKCC2 
in the TALH but differ in diuretic potency and efficacy, duration of the diuretic effect, pharmacokinetic prop-
erties, and safety profile23–27. The diverse chemical structures of the loop diuretics included in our experiments 
allowed structure-activity relationships between the inhibition of hNKCC1A vs. hNKCC1B. We were particularly 
interested in non-acidic compounds because they are likely to cross the BBB by passive diffusion, to a greater 
extent than bumetanide does, and could therefore be advantageous as NKCC1 inhibitors for potential therapeutic 
effects in brain diseases.
In the present study we used 8 loop diuretics of the 3 structurally different groups shown in Fig. 1 to eval-
uate structure-activity relationship of inhibition of hNKCC1A vs. hNKCC1B. For comparison with loop 
diuretics, two sulfonamide diuretics that act at other sites in the kidney, i.e., xipamide (4-chloro-5-sulfamoyl-2′,6′- 
salicyloxylidide) and glibenclamide (5-chloro-N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl] phenyl}
ethyl)-2-methoxybenzamide), were included in our experiments as controls.
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Expression and transport activity of hNKCC1A and hNKCC1B vs. endogenous NKCC1 in injected 
and uninjected Xenopus laevis oocytes. The inhibitory potency of several diuretics on the transport 
activity of hNKCC1A or hNKCC1B was determined upon heterologous expression of hNKCC1 in Xenopus laevis 
oocytes. Xenopus oocytes have low endogenous expression of NKCC128, which therefore does not contribute 
greatly to the results obtained with the heterologously expressed NKCC1 isoforms. This was verified by Western 
blot in the Xenopus laevis oocytes used here, showing a low expression (Fig. 2A,B) and transport activity (Fig. 2C) 
of endogenous NKCC1.
Following injection of hNKCC1A and hNKCC1B, NKCC1 protein expression in the oocytes significantly 
increased as expected (Fig. 2B). No size difference was seen for NKCC1B versus NKCC1A in the Western blots 
(Fig. 2A), because with 16 amino acids missing in NKCC1B the size difference is very small. However, as described 
in the Methods section, the identity of NKCC1B was proven by sequencing the cDNA construct. Heterologous 
expression of hNKCC1A in Xenopus oocytes increased the 86Rb+ uptake in median 10.3 fold (interquartile range: 
Figure 1. Chemical structures of clinically approved loop diuretics. According to their structures, the 
drugs were assigned to three groups. Several members of each group were tested for their potency to inhibit 
hNKCC1A vs. hNKCC1B.
www.nature.com/scientificreports/
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5.68–15.9; 21 independent experiments) compared to the uninjected oocytes (Fig. 2D). Respective figures for 
hNKCC1B were 9.3 fold (interquartile range: 6.44–18.7; 20 independent experiments) (Fig. 2D), indicating that 
both splice variants of hNKCC1 transported 86Rb+ with similar efficacy.
Inhibitory potency of bumetanide in the hNKCC1A/B oocyte assay. Bumetanide inhibited the 
86Rb+ uptake in oocytes expressing NKCC1A or NKCC1B in a dose-dependent manner (Fig. 3A, gray bars). The 
86Rb+ uptake was reduced to the level observed in uninjected oocytes at bumetanide concentrations between 30 
and 100 µM, as previously observed for hNKCC1A29. The endogenous contribution to NKCC-mediated 86Rb+ 
uptake in the uninjected oocytes was very small, as illustrated by bumetanide inhibition of the 86Rb+ uptake in 
uninjected oocytes (Fig. 3A, black bars), in agreement with earlier observations28. To deduct the contribution 
from the endogenous NKCC1, bumetanide-sensitive 86Rb+ uptake in uninjected oocytes was established in par-
allel and subtracted from the 86Rb+ uptake obtained in the hNKCC1A/B-expressing oocytes prior to determina-
tion of the IC50 for hNKCC1A or hNKCC1B, as explained in Methods. The hNKCC1A displayed an average IC50 
for bumetanide of 0.945 µM (calculated individually from n = 7). The respective average IC50 for hNKCC1B was 
0.842 µM (calculated individually from n = 7), which was not significantly different from the IC50 of bumetanide 
for hNKCC1A. Thus, bumetanide inhibited both hNKCC1 splice variants with about the same potency (Table 1, 
Fig. 3).
Inhibitory potency of other loop diuretics in the hNKCC1A/B assay. In addition to bumetanide, 7 
other loop diuretics (furosemide, piretanide, azosemide, torasemide, tripamide, ethacrynic acid, ticrynafen) were 
tested for hNKCC1A vs. hNKCC1B inhibition in the same manner as bumetanide. Measured IC50s are shown 
Figure 2. Heterologous expression of hNKCC1A and hNKCC1B in Xenopus laevis oocytes, determined by 
Western blotting, and the effect on transport activity, measured by 86RB+ uptake in the absence of NKCC1 
inhibitors. (A) Representative Western blots of hNKCC1A and hNKCC1B protein expression in injected 
oocytes as well as endogenous NKCC1 in uninjected oocytes determined with the anti-NKCC1 antibody 
ab59791. The membrane was cut at 70 kDa in order to perform anti-NKCC1 and anti-β-actin immunostainings 
in separate containers (for more details see Suppl. Figure 1). In B–D, data are shown as means ± SEM. 
Significant differences to uninjected controls is indicated by asterisks (*P < 0.05; *P < 0.01; ****P < 0.0001). 
(B) Quantitative data on protein expression of endogenous NKCC1, hNKCC1A, and hNKCC1B after 
normalization to the reference signals of ß-actin. Data are from 4 (uninjected controls) and 7 (hNKCC1A, 
hNKCC1B) independent experiments, with 1–4 oocytes per experiment. Protein expression of hNKCC1A 
vs. hNKCC1B was not significantly different. (C) Absolute values showing 86RB+ uptake in uninjected 
control oocytes (reflecting endogenous NKCC activity) vs. uptake in oocytes expressing either hNKCC1A 
or hNKCC1B. (D) Fold increase in 86RB+ uptake by oocytes expressing either hNKCC1A or hNKCC1B 
compared to uninjected oocytes. Data in (C) and (D) are from 22 (uninjected controls), 21 (hNKCC1A) and 20 
(hNKCC1B) independent experiments, with 4–20 oocytes per experiment.
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in Table 1. None of these drugs inhibited hNKCC1B significantly more potently than hNKCC1A. Although the 
average IC50 of piretanide for hNKCC1B was 50% lower than its IC50 for hNKCC1A, this difference was not statis-
tically significant. Similarly, although ticrynafen and ethacrynic acid tended to inhibit hNKCC1A more potently 
than hNKCC1B (Table 1), the differences were not significant.
Interestingly, azosemide was ~4-times more potent to inhibit the two hNKCC1 variants than bumetanide. The 
rank order of inhibitor potencies was azosemide > bumetanide ≥ torasemide ≥ furosemide ≥ piretanide >> eth-
acrynic acid >> ticrynafen. Thus, loop diuretics lacking a sulfamoyl moiety (ethacrynic acid, ticrynafen) were 
the least potent compounds. An exception was tripamide, which contains a sulfamoyl moiety (Fig. 1) but did 
not inhibit hNKCC1 splice variants in concentrations up to 1000 µM. Furthermore, xipamide and glibencla-
mide, which contain a sulfamoyl moiety but do not act at the TALH, did not inhibit the NKCC1 splice variants. 
Ethacrynic acid’s inhibitory effect on hNKCC1A and hNKCC1B was highly variable between experiments, in 
contrast to the other tested drugs.
Comparison of the potency of loop diuretics to inhibit hNKCC1A vs. hNKCC1B activity in the 
Xenopus oocyte heterologous expression system. To determine correlation of the IC50s, these values 
were plotted for the tested loop diuretics for hNKCC1A and hNKCC1B (Fig. 4). Correlation analysis of the IC50s 
obtained for hNKCC1A vs. hNKCC1B yielded a correlation coefficient of 0.9906, P < 0.001, indicating a strong 
correlation between the inhibitory potency of these compounds on the human NKCC1 splice variants tested here 
(Fig. 4). Only piretanide exhibited a trend for more potent inhibition of hNKCC1B.
Discussion
To our knowledge this is the first study addressing the inhibitory action of structurally diverse loop diuretics on 
hNKCC1 and its major splice variants hNKCC1A and hNKCC1B. As shown in Table 2, only loop diuretics of the 
5-sulfamoylbenzoic acid derivative group have been tested previously for their inhibitory activity on NKCC1. In 
these previous studies, benzmetanide was the most potent NKCC1 inhibitor, followed by bumetanide, piretanide 
and furosemide. A similar rank order of inhibitory potencies was determined for NKCC2 (Table 2). IC50s of 
bumetanide and furosemide for inhibition of NKCC1 in native cells were similar to respective IC50s determined 
Figure 3. Effect of bumetanide on hNKCC1A- and hNKCC1B-mediated 86Rb+ uptake in Xenopus oocytes.  
(A) A representative experiment demonstrating the inhibitory effect of 0.03–100 µM bumetanide on 86Rb+ 
uptake (in CPM, counted for 10 minutes) in hNKCC1A- and hNKCC1B-expressing oocytes and on batch-
matched uninjected oocytes. Data are shown as median of n = 5–10 oocytes per condition and error bars 
illustrate the interquartile range. (B) Dose-inhibition curve of bumetanide on hNKCC1A- and hNKCC1B-
mediated 86Rb+ uptake (corrected for endogenous NKCC contribution in uninjected oocytes) normalized to 
control (0 µM bumetanide) and averaged across 7 experiments, with the IC50 calculated from each individual 
experiment prior to averaging.
www.nature.com/scientificreports/
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in heterologous systems (Table 2). However, it has not been studied previously whether the NKCC1 splice variants 
NKCC1A and NKCC1B differ in their pharmacological sensitivity, whereas such studies exist for splice variants 
of NKCC2 (Table 2).
In the present study, 8 loop diuretics of the 3 structurally different groups shown in Fig. 1 were used to evaluate 
structure-activity relationship of inhibition of hNKCC1A vs. hNKCC1B. Based on their structure, these drugs 
may be also differentiated into acidic and basic compounds. Furthermore, two sulfamoyl derivatives that do 
not act on NKCC2 (Table 2), i.e., the thiazide diuretic xipamide and the antidiabetic drug glibenclamide, were 
included in our experiments. As expected, only loop diuretics inhibited the hNKCC1 splice variants, whereas 
xipamide and glibenclamide were inactive. However, marked differences were observed across the diverse loop 
diuretics.
Azosemide was the most potent inhibitor of hNKCC1, inhibiting both splice variants with about the same 
efficacy. Azosemide lacks the carboxylic group of the 5-sulfamoylbenzoic acid derivatives (Fig. 1), demonstrating 
that this carboxylic group is not needed for potent inhibition of NKCC1. Clinically, azosemide has about the same 
Loop diuretic
IC50 for hNKCC1A IC50 for hNKCC1B
Ratio hNKCC1A/ 
hNKCC1BIC50 (µM) (range)
Relative to 
bumetanide (=1) IC50 (µM) (range)
Relative to 
bumetanide (=1)
1. Sulfamoyl-benzoic acid group
Bumetanide 0.945(0.387–2.92) 1
0.842
(0.393–2.41) 1 1.12
Furosemide 5.15(4.34–13.7) 0.19
5.82
(4.73–7.27) 0.14 0.885
Piretanide 3.35(0.38–6.31) 0.28
1.66
(0.579–4.70) 0.507 2.02
2. Non-acids with sulfamoyl group
Azosemide 0.246(0.179–0.425) 3.84
0.197
(0.192–0.873) 4.27 1.25
Torasemide 6.18(1.42–8.95) 0.153
8.19
(1.31–12.4) 0.103 0.755
Tripamide N.E. (up to 1000 µM) — N.E. (up to 1000 µM) — —
3. Non-sulfonamides
Ethacrynic acid 1678(46.1–23990) 0.000563
3071
(309–4600) 0.000274 0.546
Ticrynafen 489(426–1183) 0.00193
1781
(251–2703) 0.000472 0.275
4. Non-loop diuretics with sulfamoyl group
Xipamide N.E. (up to 1750 µM) — N.E. (up to 1750 µM) — —
Glybenclamide N.E. (up to 100 µM) — N.E. (up to 100 µM) — —
Table 1. Comparison of the potency of loop diuretics from different structural groups (see Fig. 1) to inhibit 
hNKCC1A and hNKCC1B. For each drug, IC50 was at least determined in three independent experiments 
(range 3–7); the average IC50 is given as median and range of the individual IC50 values. N.E., not effective.
Figure 4. Correlation between IC50 for inhibition of hNKCC1A vs. hNKCC1B in the Xenopus oocyte assay for 
the loop diuretics evaluated in this study (see Table 1). Note that log data were used for correlation analysis.
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diuretic potency as furosemide, but both drugs are clearly less potent than bumetanide30, so the high potency of 
azosemide to inhibit the hNKCC1 splice variants was unexpected. In contrast to the short-acting diuretic bumeta-
nide, the long-acting azosemide is not a carboxylic acid, so that its tissue distribution should not be restricted by 
a high ionization rate. However, it is highly bound to plasma proteins31, which might limit its penetration into 
the brain. Indeed, in a study in which the tissue distribution of azosemide was determined 30 min following i.v. 
administration of 20 mg/kg in rats, brain levels were below detection limits (0.05 µg/g32).
Other non-acidic loop diuretics that were evaluated in the present study were torasemide and tripamide. 
Torasemide potently inhibited both hNKCC1A and hNKCC1B, while tripamide was ineffective up to 1000 µM. 
Clinically, torasemide (or torsemide) is a long-acting diuretic that is about 3 times more potent than furo-
semide30. Torasemide is highly bound to plasma proteins, which may explain its low apparent volume of dis-
tribution33. Tissue distribution studies following i.v. administration of 10 mg/kg torasemide in rats found that 
the brain:plasma concentration ratio 30 min after injection is only 0.0002434, which is even lower than the 
brain:plasma concentration ratio of bumetanide in rats (~0.01–0.0235). The poor brain penetration of azosemide32 
and torasemide34 indicates that, similar to bumetanide12, in addition to high plasma protein binding, active efflux 
at the BBB restricts brain entry of these drugs.
Tripamide, which belongs to the same group as torasemide (Fig. 1), has been shown to act as a loop diuretic36, 
but no IC50 for NKCC2 was available from the literature (Table 2). Tripamide is less well characterized than most 
other loop diuretics and standard clearance techniques indicate that it may also affect more proximal nephron 
sites36.
Compound IC50 (µM) NKCC2 Preparation
IC50 (µM) 
NKCC1** Preparation Reference
1. Endogenous NKCCs in native cells or tissue preparations
Furosemide 3–7.1* Rabbit kidney TAL; rat kidney TAL 7–23***
Turkey erythrocytes; 
mIMCD-K2 cells; chick cardiac 
cells; winter flounder intestine; 
rat erythrocytes and thymocytes
Palfrey et al.48; Schlatter et al.23; 
Frelin et al.49; O’Grady et al.50; 
Glanville et al.51; Hannaert et al.52
Bumetanide 0.2–0.33* Rabbit kidney TAL; rat kidney TAL 0.25–0.6***
Turkey erythrocytes; 
mIMCD-K2 cells; chick cardiac 
cells; winter flounder intestine; 
rat erythrocytes and thymocytes
Palfrey et al.48; Schlatter et al.23; 
Frelin et al.49; O’Grady et al.50; 
Glanville et al.51; Hannaert et al.52
Piretanide 1–1.1* Rabbit kidney TAL; rat kidney TAL 0.5–3***
Turkey erythrocytes; chick 
cardiac cells; mIMCD-K2 cells; 
winter flounder intestine; rat 
erythrocytes and thymocytes
Palfrey et al.48; Schlatter et al.23; 
Frelin et al.49; O’Grady et al.50; 
Glanville et al.51; Hannaert et al.52
Benzmetanide ? 0.05–0.3***
Turkey erythrocytes; chick 
cardiac cells; winter flounder 
intestine
Palfrey et al.48; Frelin et al.49; 
O’Grady et al.50
Azosemide 3 Rat kidney TAL ? Greven53
Torasemide 0.3 Mouse and rabbit kidney TAL ? Wittner et al.
54
Tripamide ? Standard clearance techniques in humans ? Brater and Anderson
36
Tizolemide >100 Rabbit kidney TAL ? Schlatter et al.23
Ethacrynic acid 5.1 Rabbit kidney TAL ? Schlatter et al.23
Etozolin >100 Rabbit kidney TAL ? Schlatter et al.23
Ticrynafen(tienilic acid) 410 Rabbit kidney TAL ? Schlatter et al.23
Indacrinone 12 Rabbit kidney TAL ? Schlatter et al.23
Ozolinon 11 Rabbit kidney TAL ? Schlatter et al.23
Muzolimine >100 Rabbit kidney TAL ? Schlatter et al.23
2. NKCCs expressed in heterologous systems
Furosemide 15.1 (hA), 7.2 (hB), 10.6 (hF)
hNKCC2 isoforms (A, B, 
F) expressed in Xenopus 
oocytes
~10 (Ki)*** hNKCC1 expressed in HEK-293 cells Gillen et al.
55; Carota et al.56
Bumetanide
0.54–4 (hA), 0.22 
(hB), 0.16 (hF), 2 
(mA), 0.6 (mB), 3.4 (mF)
hNKCC2 or mNKCC2 
isoforms (A, B, F) expressed 
in Xenopus oocytes
0.16–
0.28***0.68 
(hA)
hNKCC1 expressed in HEK-293 
cells; hNKCC1A expressed in 
Xenopus oocytes
Payne et al.57; Isenring et al.58; 
Plata et al.59; Carota et al.56; 
Lykke et al.60; Lykke et al.29
Table 2. Inhibitory potencies of loop diuretics for NKCC1 and NKCC2 based on a review of the literature. 
IC50s determined for endogenous NKCCs in native cells (or tissue preparations) or expressed in heterologous 
systems (Xenopus oocytes or HEK-293 cells) are separately shown. Note that several of the older studies used 
tissue preparations (such as TALH) without directly determining inhibition of NKCC2. For NKCC1, no data 
were available in the literature on isoforms of NKCC1 other than NKCC1A. Note that bumetanide is relatively 
selective for NKCCs, while furomedide and piretanide block KCCs at similar potencies than NKCCs38. 
Abbreviations: h, human; m, mouse; mIMCD-K2, mouse inner medullary collecting duct cell line; TALH, thick 
ascending limb of Henle. *NKCC2 isoforms not differentiated; **Activated state; ***NKCC1 isoforms not 
differentiated.
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Bumetanide was the second most potent NKCC1 inhibitor of the series of loop diuretics studied here, inhibit-
ing both splice variants with the same potency. The two other members of the 5-sulfamoylbenzoic acid derivatives 
group, furosemide and piretanide, were also highly potent inhibitors of the two hNKCC1 splice variants with 
IC50s in the low µmolar range. While furosemide was without any clear preference for either variant, piretanide 
tended to inhibit hNKCC1B twice more potently as hNKCC1A, although the difference was not statistically 
significant.
The two members of the non-sulfonamide group, ethacrynic acid and ticrynafen, were markedly less potent 
in inhibiting the hNKCC1 splice variants than loop diuretics containing a sulfamoyl moiety, with the excep-
tion of tripamide. This may indicate that the sulfamoyl moiety is a prerequisite for potent inhibition of NKCC1. 
Interestingly, both compounds were moderately more potent in inhibiting hNKCC1A than hNKCC1B. While the 
low potency of ticrynafen to inhibit hNKCC1 splice variants was in line with its low potency to inhibit NKCC2, 
this was not the case with ethacrynic acid, which is a potent diuretic drug (Table 2) with a clinical efficacy similar 
to that of furosemide30.
Overall, the present data indicate that loop diuretics have no significant hNKCC1A/hNKCC1B selectiv-
ity, when hNKCC1-mediated transport is measured at the transporters’ activated state. Full-length NKCC1 
(NKCC1A) comprises ~1200 amino acids and has a molecular weight of 130–132 kDa37. The predicted 
three-dimensional topology of NKCC1 shows 12 α-helical transmembrane (TM) domains which are flanked 
by hydrophilic amino- and carboxyl-terminal regions38. The shorter NKCC1B splice variant, lacking exon 21, 
was first detected by partial cloning in mouse brain tissue19. Exon 21 encodes 16 amino acid residues from the 
carboxyl (C) terminus of the NKCC1 protein. The 16 amino acids fragment was shown to contain a dileucine 
motif as a basolateral sorting motif, therefore targeting NKCC1A to the basolateral membrane of epithelia39. The 
absence of exon 21 in NKCC1B does not appear to affect NKCC1 function37 and, as demonstrated by the present 
data, susceptibility to inhibition by loop diuretics. Interestingly, exon 21 of NKCC1A is also absent from NKCC2, 
which is involved in the apical expression of the latter transporter, although there are other important signals in 
the C-terminus of NKCC2 that take it to the apical membrane39. It is generally thought that loop diuretics bind in 
the translocation pocket of NKCC and that the binding site may be near the intracellular end of the pocket40–44.
One may thus argue that the outcome of this study was essentially predictable given that NKCC1B is identical 
to NKCC1A except for the exclusion of a single exon in the C-terminus. In particular, NKCC2 also lacks this exon 
and is as sensitive to bumetanide as is NKCC1A (Table 2). Thus, loop diuretics may not be an ideal starting point 
to synthesize NKCC1B-selective inhibitors. However, as demonstrated by azosemide, potency to inhibit NKCC2 
(Table 2) did not predict its high potency to inhibit hNKCC1A/B in the present study.
Based on the tissue distribution and cellular localization of NKCC1 and its splice variants18,37,38,45,46, a 
NKCC1B-selective inhibitor may lack ototoxic effects while enabling inhibition of neuronal NKCC1. However, 
it may be difficult to develop NKCC1B-selective inhibitors because the only difference between NKCC1A and 
NKCC1B is the lack of the small exon 21, a region that is very poorly conserved, predicted to be unstructured, and 
seems unlikely to be involved in an important way with either ion translocation or diuretic inhibition and proba-
bly not to a significant extent to the phosphorylation-activation mechanism38. One feasible plan to tackle the goal 
would be a high-throughput screening (HTS) assay for the splice variants of the hNKCC1 cotransporter similar 
to the HTS approach recently described for hNKCC1 expressed in human embryonic kidney (HEK) cell line47. 
The latter cell-based Rb+ flux assay has been used to screen for NKCC1 inhibitors in a focused library of 1450 
compounds, followed by a full HTS of 1.2 million compounds, using the Ion Channel Reader (ICR) technology 
for detecting intracellular concentration of Rb+ in cell lysates47. IC50 for bumetanide (1.16 µM) determined by the 
latter technology was similar to the bumetanide IC50s reported here, but none of the blind compounds reported 
by Gill et al.47 reached the potency of azosemide determined in the present study.
In conclusion, the main findings of the present study on structure-activity analyses of 10 chemically diverse 
diuretics are that (1) none of the examined compounds were significantly more effective to inhibit NKCC1B 
than NKCC1A, and (2) azosemide was more potent than any other diuretic, including bumetanide, to inhibit the 
two NKCC1 variants. The latter finding is particularly interesting because, in contrast to bumetanide, which is a 
relatively strong acid (pKa = 3.6), azosemide is not acidic (pKa = 7.38), which should favor its tissue distribution 
by passive diffusion. Lipophilicity (logP) of the two drugs is in the same range (2.38 for azosemide vs. 2.7 for 
bumetanide). Furthermore, azosemide has a longer duration of action than bumetanide, which results in supe-
rior clinical efficacy26 and may be an important advantage for treatment of brain diseases with abnormal cellular 
chloride homeostasis.
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